TY  - GEN
AU  - Ara,R
AU  - Pandor,A
AU  - Stevens,J
AU  - Rafia,R
AU  - Ward,S E
AU  - Rees,A
AU  - Durrington,P N
AU  - Reynolds,T M
AU  - Wierzbicki,A S
AU  - Stevenson,M
TI  - Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
SN  - 2047-4881
PY  - 2012///0919
KW  - Atorvastatin
KW  - Bayes Theorem
KW  - Cardiovascular Diseases
KW  - drug therapy
KW  - Clinical Trials, Phase III as Topic
KW  - Cost-Benefit Analysis
KW  - Drug Costs
KW  - Drug Prescriptions
KW  - economics
KW  - Drugs, Generic
KW  - administration & dosage
KW  - Fluorobenzenes
KW  - Heptanoic Acids
KW  - Humans
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Markov Chains
KW  - Medication Adherence
KW  - Models, Economic
KW  - Pyrimidines
KW  - Pyrroles
KW  - Quality Indicators, Health Care
KW  - Quality-Adjusted Life Years
KW  - Randomized Controlled Trials as Topic
KW  - Rosuvastatin Calcium
KW  - Secondary Prevention
KW  - Simvastatin
KW  - Sulfonamides
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1177/1741826711406616
ER  -